Vericel Corporation (VCEL) News

Vericel Corporation (VCEL)

Today's Latest Price: $25.20 USD

0.24 (0.96%)

Updated Nov 27 1:00pm

Add VCEL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

Filter VCEL News Items

VCEL News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest VCEL News From Around the Web

Below are the latest news stories about Vericel Corp that investors may wish to consider to help them evaluate VCEL as an investment opportunity.

Vericel (VCEL) Investor Presentation - Slideshow

The following slide deck was published by Vericel Corporation in conjunction with this event....

SA Transcripts on Seeking Alpha | September 18, 2020

MediWound: An Underfollowed Opportunity At A Discount

MediWound (MDWD) has popped up on my scanner several times over the past couple of years following some potent company press releases and catalysts. Admittedly, I would take a look at the headline and then check the ticker only to see a big move followed by a fade, so I...

Biologics on Seeking Alpha | September 8, 2020

World Cell & Gene Therapy Markets, 2025 - Leading Players are Gilead Sciences, Spark Therapeutics, Novartis, Organogenesis, Amgen, Osiris Therapeutics, Dendreon, and Vericel - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cell & Gene Therapy Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included The study considers the present scenario of the cell and gene therapy market and its market dynamics for the period 2019-2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and suppl

Business Wire | August 6, 2020

Vericel (VCEL) Q2 2020 Earnings Call Transcript | The Motley Fool

VCEL earnings call for the period ending June 30, 2020.

The Motley Fool | August 6, 2020

Vericel EPS beats by $0.02, beats on revenue

Vericel (VCEL): Q2 GAAP EPS of -$0.18 beats by $0.02.Revenue of $20.01M (-23.5% Y/Y) beats by $0.7M.Press Release...

Seeking Alpha | August 5, 2020

Vericel Reports Second Quarter 2020 Financial Results

Product Revenues of $20.0 Million Reported for the Second Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE…

GlobeNewswire | August 5, 2020

Vericel to Report Second-Quarter 2020 Financial Results on August 5, 2020

CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe…

GlobeNewswire | July 22, 2020

Do Options Traders Know Something About Vericel (VCEL) Stock We Don't?

Investors need to pay close attention to Vericel (VCEL) stock based on the movements in the options market lately.

Yahoo | July 15, 2020

Vericel Announces Preliminary Second Quarter 2020 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., July 09, 2020 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced.

Yahoo | July 9, 2020

Vericel Announces Submission of Biologics License Application to the FDA for NexoBrid for the Treatment of Severe Thermal Burns

CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced the submission of a Biologics License Application…

GlobeNewswire | June 30, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6056 seconds.